-
Mashup Score: 3Durvalumab Significantly Benefits SCLC Patients - 11 day(s) ago
In the global phase III ADRIATIC trial, AstraZeneca’s PD-L1 inhibitor durvalumab (Imfinzi) demonstrated significantly improved progression-free survival and overall survival in patients with limited-stage small cell lung cancer (SCLC) whose disease did not progress following concurrent chemoradiotherapy (cCRT) compared with a placebo after cCRT; data will be presented at an upcoming medical meeting. A second arm of the trial is comparing the effectiveness of durvalumab monotherapy with durvalumab plus the CTLA4 inhibitor tremelimumab (Imjudo) in the same patient population. Durvalumab is approved in the United States and several other countries for the treatment of extensive-stage SCLC based on results of the phase III PACIFIC trial.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Home - 24 day(s) ago
Learn how DLL3 and T-cell engager technology together have the potential to address unmet needs in SCLC and high-grade neuroendocrine cancers.
Source: www.dll3possibilities.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 0Evaluating PD-L1 Therapy in SCLC - 30 day(s) ago
Ariel Lopez-Chavez, MD, discusses some of the research on evaluating PD-L1 therapy for patients with small cell lung cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Routine Prophylactic Cranial Irradiation for SCLC Questioned - 2 month(s) ago
Investigators found no significant survival benefit after prophylactic cranial irradiation in patients with SCLC who did not have preexisting brain metastases.
Source: www.medscape.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 3Optimizing SCLC Outcomes with Early Action - 2 month(s) ago
Federico Albrecht, MD, discusses Miami Cancer Institute’s specific protocol for hospitalized patients with small cell lung cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 69Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases - 4 month(s) ago
Lurbinectedin was evaluated in a multicenter, open-label, Basket phase 2 study in nine cohorts of patients with different difficult-to-treat tumor types to establish the proof of concept for clinical development [1–5]. Based on the results observed in a cohort of 105 patients with pretreated small cell lung cancer (SCLC) [1], lurbinectedin was approved first in the United States [6] and later in several other countries worldwide. Furthermore, and based on these same results, the European Society of Medical Oncology (ESMO) and the US National Comprehensive Cancer Network (NCCN) guidelines incorporated lurbinectedin as an option for the second-line treatment of SCLC patients [7,8].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Home - 4 month(s) ago
Learn how DLL3 and T-cell engager technology together have the potential to address unmet needs in SCLC and high-grade neuroendocrine cancers.
Source: www.dll3possibilities.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 2CTG Labs - NCBI - 5 month(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 38
First-line chemotherapy plus immunotherapy (CT-IO) have recently demonstrated survival benefit over CT alone in Extensive-Stage Small Cell Lung Cancer (ES-SCLC), based on randomized phase 3 studies. This retrospective multicentre study assessed the real-world use and effectiveness of CT-IO in ES-SCLC patients.
Source: www.clinical-lung-cancer.comCategories: General Medicine News, Hem/OncsTweet
News— Durvalumab Significantly Benefits #SCLC Patients. https://t.co/8s3lYM8XSd https://t.co/Bfy6g4nr5t